For the voting questions, use the following scale identifying level of confidence - with 1 being the lowest or no confidence and 5 representing a high level of confidence.		Ross	Brewington	Cinquegrani	Kazerooni	Lahey	Miller	Speir	Tyagi	Thomas	Stephens	Waldren	Voting Member Average	Overall Average
1. a	1. How confident are you that the following are standalone, meaningful primary health outcomes in research studies of cerebrovascular disease treatment technologies: a. Major disabling stroke: defined as stroke in the treated vascular territory that results in a Modified Rankin Scale (mRS) $\geq$ 3;	5	4	4	5	4	4	4	4	4	4	3	4.22	4.09
1. b	Decrease in mRS of ≥ 2 points compared to baseline;	2	2	4	4	2	4	3	5	4	4	2	3.33	3.27
1. c	mRS of $\leq$ 2 or equal to pre-stroke mRS (if the pre-stroke mRS was $>$ 2);	3	3	3	3	2	4	3	5	4	4	2	3.33	3.27
1. d	Other kinds of stroke, such as major ipsilateral stroke or morbid stroke.	4	3	4	3	3	3	4	3	3	1	2	3.33	3.00
	1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence													

	the voting questions, use the following scale identifying level of confidence - with 1 being the lowest or no confidence and 5 esenting a high level of confidence.	Ross	Brewington	Cinquegrani	Kazerooni	Lahey	Miller	Speir	Tyagi	Thomas	Stephens	Waldren	Voting Member Average
2. a	<ol> <li>How confident are you that the following are standalone, meaningful primary health outcomes in research studies of cerebrovascular disease treatment technologies: a. Hospitalization length of stay for index procedure;</li> </ol>	2	2	1	3	1	2	2	3	1	2	1	1.89
2. b	b. Number of unscheduled re-admissions that are related to cerebrovascular disease	5	3	2	3	2	2	2	4	2	3	2	2.78
2. c	c. Discharge disposition to rehabilitation (home vs. inpatient facility)?	4	3	3	3	4	3	3	3	2	3	2	3.00
	1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence												

Overall Average

1.82

2.73

3.00

	e voting questions, use the following scale identifying level of confidence - with 1 being the or no confidence and 5 representing a high level of confidence.	Ross	Brewington	Cinquegrani	Kazeroon	Lahey	Miller	Speir	Tyagi	Thomas	Stephens	Waldren	Voting Member Average	Overall Average
3. a	standalone, meaningful primary health outcome measures in clinical research studies of cerebrovascular disease treatment technologies: a. The Modified Rankin Scale	4	5	4	5	5	4	4	4	5	4	4	4.44	4.36
3. b	b. The National Institutes of Health Stroke Scale (NIHSS);	4	5	4	4	4	1	4	1	2	2	2	3.22	3.00
	1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence													

	the voting questions, use the following scale identifying level of confidence - with 1 being the lowest or no fidence and 5 representing a high level of confidence.	Ross	Brewington	Cinquegrani Kazerooni	Lahey	Miller	Speir	Tyagi	Thomas	Stephens	Waldren	Voting Member Average	Overall Average
4.	How confident are you that using EQ-5D to measure quality of life: a. Is adequate measure which reflects the patient experience in the context of cerebrovascular disease studies;	4	4	3 4	4	2	4	4	4	4	4	3.67	3.73
4.	b. Should be included as standalone, meaningful primary health outcome measure in research st	3	2	2 3	1	2	3	3	2	4	3	2.55	2.55
4.	c Should be included as a composite, meaningful primary health outcomes in research studies a	4	2	3 2	1	1	3	3	3	3	3	2.55	2.55
4.	d d. Should be included as secondary health outcomes in research studies.	5	5	4 5	5	3	4	5	4	5	5	4.55	4.55
	1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence												